SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Hepatocellular CarcinomaSBRTImmune Checkpoint BlockadeTyrosine Kinase Inhibitor

Interventions

DRUG

adbelimumab

adbelimumab：1200mg iv d1 q3w

PROCEDURE

SBRT

SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;

DRUG

apatinib

apatinib：250mg po, qd

All Listed Sponsors

lead

Fujian Cancer Hospital

OTHER_GOV